SENP6抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela cells, K562 cells, Primary antibody: P05270(SENP6 Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P05270(SENP6 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SENP6 antibody is a crucial tool in studying the role of SENP6 (Sentrin/SUMO-specific protease 6), a deSUMOylating enzyme belonging to the ubiquitin-like protease family. SENP6 regulates post-translational protein modification by removing SUMO (Small Ubiquitin-like Modifier) chains or monomers from target proteins, thereby modulating their activity, localization, or stability. This enzyme primarily processes poly-SUMO chains, distinguishing it from other SENP family members that preferentially cleave SUMO precursors or mono-SUMOylated substrates. SENP6 is implicated in diverse cellular processes, including DNA damage repair, chromatin remodeling, cell cycle progression, and the regulation of the NF-κB and Hippo signaling pathways. Dysregulation of SENP6 has been linked to diseases such as cancer, neurodegenerative disorders, and cardiovascular conditions.

Antibodies targeting SENP6 enable researchers to investigate its expression levels, subcellular localization (predominantly nuclear), and interactions with substrates like SUMO2/3-conjugated proteins. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, immunoprecipitation, and chromatin immunoprecipitation (ChIP). Given the structural similarity among SENP proteases, high specificity of SENP6 antibodies is critical to avoid cross-reactivity. Commercial SENP6 antibodies are often validated using knockout cell lines or siRNA-mediated knockdown to confirm target specificity. Research utilizing these antibodies has advanced understanding of SUMOylation dynamics in cellular stress responses, genomic stability, and disease mechanisms, highlighting SENP6 as a potential therapeutic target.